Raptor Pharmaceutical has launched Quinsair levofloxacin inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Germany and Denmark, the company said. According to Raptor, it plans to launch Quinsair in Canada and in additional European countries later this year. Raptor acquired Quinsair, formerly called Aeroquin, in … [Read more...] about Raptor launches Quinsair inhaled levofloxacin in Europe
Business
Chiesi reports significant growth in respiratory drug sales, R&D expenditures for 2015
Chiesi has reported a greater than 9% increase in revenue from 2014 to 2015, with an almost 20% increase in sales of Foster (Fostair) beclamethasone/formoterol inhalers and an unspecified increase in sales of Clenil beclamethasone products. The increase was also partly attributed to the "swift and smooth" integration of Cornerstone Therapeutics,which Chiesi acquired … [Read more...] about Chiesi reports significant growth in respiratory drug sales, R&D expenditures for 2015
BI and Propeller Health announce new partnership
Boehringer Ingelheim and Propeller Health have announced a new partnership that will allow COPD and asthma patients using Respimat inhalers "to enroll at select US health systems in a new program that is designed to determine how Propeller’s novel health technology tool for the Respimat inhaler impacts adherence rates and patient engagement." Propeller received 510(k) … [Read more...] about BI and Propeller Health announce new partnership
Apotex launches generic version of Nasonex in the US
Apotex has launched a generic version of Merck's Nasonex mometasone furoate nasal spray in the United States, the company said. In June 2012, A US District Court judge upheld a Merck patent on mometasone furoate (US Patent No. 6,127,353) but ruled that Apotex's nasal spray did not infringe on that patent. According to the FDA, the agency approved Apotex's ANDA for … [Read more...] about Apotex launches generic version of Nasonex in the US
Aradigm’s Pulmaquin will get EMA review under centralized procedure
Aradigm Corporation has announced that the EMA will review an Aradigm MAA for Pulmaquin inhaled liposomal ciprofloxacin under the centralized authorization procedure. According to the company, "Aradigm requested, and was granted, the centralized pathway on the basis that Pulmaquin represents a significant technical innovation for the potential treatment of non-cystic … [Read more...] about Aradigm’s Pulmaquin will get EMA review under centralized procedure
Vectura to acquire Skyepharma
Inhaled drug manufacturers Vectura and Skyepharma have announced a merger agreement in which Vectura will acquire Skyepharma for a total of £441 million ($638 million). Both boards have approved the merger. Vectura previously acquired Activaero in 2014. Vectura CEO James Ward-Lilley will continue as CEO and Vectura Chairman Bruno Angelici will continue as Chairman … [Read more...] about Vectura to acquire Skyepharma
MannKind announces 4th quarter results, management changes
According to MannKind Corporation, the company's net loss for 2015 was $368.4 million, and its cash and cash equivalents as of the end of 2015 totaled $59.1 million. The company also said that it has hired former Amgen VP, Global Commercial Lead Michael E. Castagna as its Chief Commercial Officer, effective immediately, and announced the resignation of Chief Operating … [Read more...] about MannKind announces 4th quarter results, management changes
Children’s Flonase now available OTC in the United States
GSK Consumer Healthcare has announced that Children's Flonase fluticasone propionate nasal spray is now available over the counter in the US. The FDA approved OTC sales of Flonase in July 2014, and the product has been available over the counter in the US since February 2015. Children's Flonase appears to be effectively identical to regular Flonase, with 50 mcg of … [Read more...] about Children’s Flonase now available OTC in the United States
Cannabinoid developer to collaborate with intranasal delivery company on epilepsy therapy
Australian medical cannabis company MGC Pharmaceuticals has signed a collaboration agreement with Israeli device developer SipNose for development of a cannabinoid therapy for the treatment of epilepsy, the company said. The agreement includes an option for a global license for use of the SipNose device to deliver cannabinoids for epilepsy. According to MGC, the … [Read more...] about Cannabinoid developer to collaborate with intranasal delivery company on epilepsy therapy
Savara Pharmaceuticals raises $20 million for AeroVanc development
Savara Pharmaceuticals has announced the completion of a $20 million financing round to fund a pivotal Phase 3 clinical trial of its AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis patients. The company says that it expects enrollment for the study to begin by the end of the year. In February 2015, Savara announced positive … [Read more...] about Savara Pharmaceuticals raises $20 million for AeroVanc development